Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
Oncternal Therapeutics, Inc. (GTXI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 10/04/2023 |
4
| Leavitt Chase C. (General Counsel/Secretary) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Disposed/sold 65,000 options
@ $6.46, valued at
$419.9k
Disposed/sold 55,519 options
@ $1.94, valued at
$107.7k
Disposed/sold 28,750 options
@ $1.04, valued at
$29.9k
Disposed/sold 210,000 options
@ $0.96, valued at
$201.6k
Granted 65,000 options
@ $0
Granted 55,519 options
@ $0
Granted 28,750 options
@ $0
Granted 210,000 options
@ $0
Granted 235,000 options
@ $0.31, valued at
$72.9k
|
|
| 10/04/2023 |
4
| Yazji Salim (Chief Medical Officer) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Disposed/sold 354,400 options
@ $5.3, valued at
$1.9M
Disposed/sold 92,075 options
@ $1.94, valued at
$178.6k
Disposed/sold 55,000 options
@ $1.04, valued at
$57.2k
Disposed/sold 210,000 options
@ $0.96, valued at
$201.6k
Granted 354,400 options
@ $0
Granted 92,075 options
@ $0
Granted 55,000 options
@ $0
Granted 210,000 options
@ $0
Granted 70,600 options
@ $0.31, valued at
$21.9k
|
|
| 10/04/2023 |
4
| BREITMEYER JAMES B (CEO) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Disposed/sold 100,000 options
@ $5.76, valued at
$576k
Disposed/sold 66,890 options
@ $3.33, valued at
$222.7k
Disposed/sold 750,000 options
@ $7.05, valued at
$5.3M
Disposed/sold 637,000 options
@ $1.94, valued at
$1.2M
Disposed/sold 123,750 options
@ $1.04, valued at
$128.7k
Disposed/sold 650,000 options
@ $0.96, valued at
$624k
Granted 100,000 options
@ $0
Granted 66,890 options
@ $0
Granted 750,000 options
@ $0
Granted 637,000 options
@ $0
Granted 123,750 options
@ $0 |
|
| 10/04/2023 |
4
| VINCENT RICHARD G (CFO) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Disposed/sold 75,000 options
@ $5.76, valued at
$432k
Disposed/sold 35,120 options
@ $3.33, valued at
$116.9k
Disposed/sold 280,000 options
@ $7.05, valued at
$2M
Disposed/sold 109,579 options
@ $1.94, valued at
$212.6k
Disposed/sold 28,750 options
@ $1.04, valued at
$29.9k
Disposed/sold 210,000 options
@ $0.96, valued at
$201.6k
Granted 75,000 options
@ $0
Granted 35,120 options
@ $0
Granted 280,000 options
@ $0
Granted 109,597 options
@ $0
Granted 28,750 options
@ $0 |
|
| 10/04/2023 |
4
| Krishnan Rajesh (Chief Technical Officer) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Disposed/sold 75,000 options
@ $4.3, valued at
$322.5k
Disposed/sold 40,000 options
@ $5.76, valued at
$230.4k
Disposed/sold 12,470 options
@ $3.33, valued at
$41.5k
Disposed/sold 160,000 options
@ $4.59, valued at
$734.4k
Disposed/sold 177,050 options
@ $1.94, valued at
$343.5k
Disposed/sold 28,750 options
@ $1.04, valued at
$29.9k
Disposed/sold 220,000 options
@ $0.96, valued at
$211.2k
Granted 75,000 options
@ $0
Granted 40,000 options
@ $0
Granted 12,470 options
@ $0
Granted 160,000 options
@ $0 |
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results - Obtained U.S. FDA IND clearance for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor signaling inhibitors - Dosed the first patient in our Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma - Cash runway extended into 2025, with $45.5 million in cash, cash equivalents and short-term investments and no debt as of June 30, 2023 - Management to host webcast today at 5:00 pm ET SAN DIEGO, August 10, 2023 -- Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutic..." |
|
| 07/05/2023 |
4
| BREITMEYER JAMES B (CEO) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 47,992 shares
@ $0.36, valued at
$17.3k
Paid exercise price by delivering 4,007 shares
@ $0.36, valued at
$1.4k
|
|
| 07/05/2023 |
4
| Leavitt Chase C. (General Counsel/Secretary) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 10,305 shares
@ $0.36, valued at
$3.7k
|
|
| 07/05/2023 |
4
| VINCENT RICHARD G (CFO) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 7,069 shares
@ $0.36, valued at
$2.5k
|
|
| 07/05/2023 |
4
| Yazji Salim (Chief Medical Officer) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 16,299 shares
@ $0.36, valued at
$5.9k
|
|
| 07/05/2023 |
4
| Krishnan Rajesh (Chief Technology Officer) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 10,897 shares
@ $0.36, valued at
$3.9k
|
|
| 06/30/2023 |
4
| THEUER CHARLES (Director) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Granted 25,000 options
@ $0.3553, valued at
$8.9k
|
|
| 06/30/2023 |
4
| CARTER MICHAEL G (Director) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Granted 25,000 options
@ $0.3553, valued at
$8.9k
|
|
| 06/30/2023 |
4
| LARUE WILLIAM R (Director) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Granted 25,000 options
@ $0.3553, valued at
$8.9k
|
|
| 06/30/2023 |
4
| Wills Robert James (Director) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Granted 25,000 options
@ $0.3553, valued at
$8.9k
|
|
| 06/30/2023 |
4
| MAZANET ROSEMARY (Director) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Granted 25,000 options
@ $0.3553, valued at
$8.9k
|
|
| 06/30/2023 |
4
| Nakanishi Xin (Director) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Granted 25,000 options
@ $0.3553, valued at
$8.9k
|
|
| 06/30/2023 |
4
| KISNER DANIEL L (Director) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Granted 25,000 options
@ $0.3553, valued at
$8.9k
|
|
| 06/30/2023 |
4
| HALE DAVID F (Director) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Granted 37,500 options
@ $0.3553, valued at
$13.3k
|
|
| 06/30/2023 |
4
| DeSimone Jill (Director) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Granted 25,000 options
@ $0.3553, valued at
$8.9k
|
|
| 06/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/16/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/16/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/05/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results|
Docs:
|
"Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results - Phase 1/2 study initiated for ONCT-808, our autologous CAR-T targeting ROR1-expressing hematologic malignancies, with initial clinical data expected in late 2023 - Final IND-enabling studies completed for ONCT-534, our novel dual-action androgen receptor inhibitor , with expected IND submission in mid-2023 - Cash runway extended into 2025, with $54.3 million in cash, cash equivalents and short-term investments and no debt as of March 31, 2023 - Management to host webcast today at 5:00 pm ET SAN DIEGO, May 4, 2023 -- Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported f..." |
|
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/03/2023 |
8-K
| Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment... |
|
|
|